Fasting glucose

Reference ranges

Optimal ranges are tighter than standard lab ranges and reflect functional-medicine targets, not the populations they were derived from. Reference bands depend on sex, age, and circumstance — Juno's lab analysis layers your profile context onto the printed range when you paste a value.

Peptide relevance

Standard metabolic screen. Pre-diabetes: 100-125; diabetes: ≥126 on two separate fastings. Pairs with fasting insulin for HOMA-IR (existing entry). GLP-1 agonists (tirzepatide, semaglutide) reliably lower fasting glucose 10-30 mg/dL in T2D / obese patients. CJC-1295 + Ipamorelin + Tesamorelin: GH-axis activation transiently raises insulin resistance, so fasting glucose can edge upward during the first 4-8 weeks — usually stabilizes thereafter as body composition improves. MK-677: known to raise fasting glucose 5-15 mg/dL within weeks — flag for users with pre-existing impaired glucose tolerance. 5-amino-1MQ: animal data suggests improved insulin sensitivity; no consistent human data. KEY CAVEATS: must be true 10-12h fast; recent illness (especially viral) acutely raises glucose; stress / dawn phenomenon affect AM readings.

Peptides that influence this marker

Documented to affect this marker. Click through for the full evidence-tiered profile.

• CJC-1295
  GHRH analog

  Transient mild fasting-glucose rise during GH-axis activation phase

• Tier 1 — Human RCTCagriSema↓· by 8–12 weeks
  Blend
• MK-677 (Ibutamoren)
  Non-peptide ghrelin mimetic (small molecule)

  Raises fasting glucose 5-15 mg/dL — flag for pre-diabetic users

• Tier 1 — Human RCTSemaglutide↓· by 8–12 weeks
  GLP-1 receptor agonist

  Lowers fasting glucose 10-30 mg/dL in T2D / obese patients

• Tier 1 — Human RCTTirzepatide↓· 8–12 weeks
  GLP-1 / GIP dual agonist

  Lowers fasting glucose 10-30 mg/dL in T2D / obese patients